Based on this, a KRAS gene mutation in A549 EGFR‐wild‐type lung cancer cells actively promotes over‐phosphorylated EGFR‐AKT levels, keeping its over‐activated level even when using EGFR‐TKIs treatment [45]. This evidence concerns the gene AKT1 and lung carcinoma.